We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




MicroRNA Panel Delivers Thyroid Cancer Diagnosis

By LabMedica International staff writers
Posted on 08 Aug 2018
A 19 microRNA panel established by using next-generation sequencing classifies indeterminate thyroid nodule samples as being either malignant or benign.

MicroRNAs (miRNAs) and short interfering RNAs (siRNA) comprise a class of about 20 nucleotides-long RNA fragments that block gene expression by attaching to molecules of messenger RNA in a fashion that prevents them from transmitting the protein synthesizing instructions they had received from the DNA. More...
MiRNAs resemble siRNAs of the RNA interference (RNAi) pathway, except miRNAs derive from regions of RNA transcripts that fold back on themselves to form short hairpins, whereas siRNAs derive from longer regions of double-stranded RNA. With their capacity to fine-tune protein expression via sequence-specific interactions, miRNAs help regulate cell maintenance and differentiation.

Patients with suspicious thyroid nodules often undergo fine needle aspiration biopsy (FNAB) to facilitate the diagnosis of malignancy. However, roughly 30% of patients who undergo this procedure receive indeterminate results. As previous studies had identified several microRNAs with altered expression in thyroid cancer, investigators at the Hadassah-Hebrew University Medical Center (Israel) utilized next-generation sequencing (NGS) technology to identify diversities in the miRNA expression profile of benign versus malignant thyroid nodules.

During the study a total of 274 samples were obtained from 102 patients undergoing thyroidectomy. Of these samples, 71% were benign and 29% were malignant. Nineteen miRNAs were identified as statistically different between benign and malignant samples. The 19 miRNA panel was used to evaluate 66 biopsy specimens from 35 patients with indeterminate pathology. Results revealed that 22 patients had malignant thyroid nodules, while 13 patients had benign thyroid nodules. Of the patients with malignancy, 15 patients were diagnosed with papillary thyroid cancer, and seven patients were diagnosed with follicular thyroid cancer. The miRNA panel's sensitivity, specificity, negative and positive predictive values, and overall accuracy were 91%, 100%, 87%, 100%, and 94%, respectively.

"Thyroid nodules are extremely common and occasionally harbor cancer," said first author Dr. Haggi Mazeh, chief of surgery at the Hadassah-Hebrew University Medical Center, "and there are currently limited options for further management, representing a clinically unmet need. Our results provided a refined list of candidate microRNA for diagnostic use, and confirmed the perception that microRNA quantification is a promising form of molecular pathology. Further studies are needed to test the clinical utility of this approach in prospective patients."

The study was published in the July 26, 2018, online edition of the journal Cancer Epidemiology, Biomarkers & Prevention.

Related Links:
Hadassah-Hebrew University Medical Center


New
Gold Member
Quality Control Material
iPLEX Pro Exome QC Panel
3-Part Differential Hematology Analyzer
Swelab Alfa Plus Sampler
New
Silver Member
Quality Control Material
NATtrol Chlamydia trachomatis Positive Control
New
Staining System
RAL DIFF-QUIK
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)

Channels

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: A simple blood test could replace surgical biopsies for early detecion of heart transplant rejection (Photo courtesy of Shutterstock)

Blood Test Detects Organ Rejection in Heart Transplant Patients

Following a heart transplant, patients are required to undergo surgical biopsies so that physicians can assess the possibility of organ rejection. Rejection happens when the recipient’s immune system identifies... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.